Prostate Cancer Diagnostics Market Summary

The global prostate cancer diagnostics market size was estimated at USD 7.72 billion in 2023 and is projected to reach USD 11.90 billion by 2030, growing at a CAGR of 6.4% from 2024 to 2030. Market growth is strongly influenced by the rising prevalence of prostate cancer worldwide, which continues to be a major health concern for aging male populations. According to an article by the American Society of Clinical Oncology (ASCO) published in March 2023, prostate cancer remains the most common cancer among men, reflecting its widespread impact and the increasing need for effective diagnostic solutions.

About 288,300 men are estimated to be diagnosed with prostate cancer in 2023. Additionally, around 1.41 million people globally were diagnosed with prostate cancer in 2020, making it the fourth most diagnosed cancer across all populations. The expanding global geriatric population, which is more prone to prostate-related health issues, along with ongoing technological advancements in cancer detection, imaging, and biomarker testing, are expected to fuel market growth throughout the forecast period.

Key Market Trends & Insights

• North America dominated the market and accounted for 44.9% share in 2023. The region benefits from advanced healthcare infrastructure, strong disease awareness, and early adoption of innovative diagnostic tools.
• Asia Pacific is anticipated to witness the fastest growth in the market, supported by improving healthcare systems, rising cancer screening programs, and increasing investments in diagnostic technologies.
• Based on end use, the outpatient facilities segment accounted for the largest revenue share in 2023. The preference for outpatient settings is rising due to their convenience, cost-effectiveness, and accessibility for routine cancer screening and follow-up procedures.
• In terms of type, the adenocarcinoma segment accounted for the largest revenue share in 2023. This is mainly because adenocarcinoma represents the most common form of prostate cancer diagnosed worldwide.
• Based on test type, confirmatory tests led the market and accounted for the largest revenue share of 66.4% in 2023. These tests play a crucial role in verifying initial screening results and guiding accurate clinical decisions.

Order a free sample PDF of the Prostate Cancer Diagnostics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 7.72 Billion
• 2030 Projected Market Size: USD 11.90 Billion
• CAGR (2024-2030): 6.4%
• North America: Largest market in 2023
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

MDx Health, Myriad Genetics, Inc., and Abbott Laboratories are some of the dominant players operating in the prostate cancer diagnostics market.

• MDxHealth is a global healthcare company that delivers precise diagnostics based on genetic information, to tailor cancer diagnosis and treatment
• Myriad Genetics, Inc. is primarily involved in the R&D and commercialization of transformative molecular diagnostics. The company operates through two divisions: diagnostics and others. The diagnostics division provides testing and collaborative development of testing while the other segment provides testing products and services to the biotechnology, medical research, and pharmaceutical industries

OPKO Health, Inc., Genomic Health., and Siemens Healthcare GmbH are some of the emerging market players functioning in the prostate cancer diagnostics market.

• OPKO Health, Inc. is a healthcare company that aims at developing, manufacturing, and marketing a varied range of products. The company operates under two reportable segments i.e., diagnostics and pharmaceuticals
• Siemens Healthcare is a medical technology company and is a manufacturer and provider of therapeutics systems and clinical diagnostics. The company’s products include automation, integrated chemistry, routine chemistry, diabetes, hematology, urinalysis, molecular testing systems, blood gas monitoring, among others

Key Players

• MDx Health
• Myriad Genetics, Inc.
• Abbott Laboratories
• Hoffman-La Roche AG
• Bayer AG
• Siemens Healthcare GmbH
• OPKO Health, Inc.
• Genomic Health.
• Pfizer Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The prostate cancer diagnostics market is set for steady expansion as rising disease prevalence, aging populations, and continuous advancements in diagnostic technologies drive demand worldwide. With greater emphasis on early detection and precision-based testing, healthcare systems are increasingly adopting advanced imaging methods, biomarker assays, and confirmatory diagnostic tools. North America continues to lead due to strong infrastructure, while Asia Pacific’s rapid growth highlights expanding access to screening and improved medical capabilities. As awareness grows and new tools enhance diagnostic accuracy, the market is poised to support better clinical outcomes, earlier interventions, and broader availability of reliable prostate cancer testing solutions.